Fig. 2 | Nature Communications

Fig. 2

From: Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target

Fig. 2

JAK-STAT pathway component alterations are common characteristics in both ANKL and NKTCL. a Somatic mutations identified in STAT3 in ANKL (n = 14) and NKTCL (n = 25) patients. b–c Ideograms of chromosome 9 (b) and 17 (c) showing the areas of copy number alterations identified in ANKL and NKTCL. Red bars indicate gains and blue bars indicate losses. Patient IDs are indicated on the left and the locations of JAK-STAT genes are displayed. Only patients with gains are shown. d JAK-STAT and PTP alterations in NKTCL. Both alterations detected in this study using reanalyzed WES data and alterations detected by Jiang et al.[11] using SNP arrays are shown. Diagonally split dual-colored rectangle indicates the presence of two alterations of different type in the same sample. e Summary of JAK-STAT alterations identified in this study and in Nakashima et al.5

Back to article page